Abstract: A system, for transcutaneous photodynamic therapy in an organ or organ segment of an organic body, includes a plurality of light applicators, a supply unit and a placement template placeable relative to the organic body for defined orientation of the light applicators. The light applicators include a needle-shaped insertion portion for transcutaneous piercing along a piercing axis, a light-emitting applicator tip at the distal end of the insertion portion, and a fixing point at a proximal distance from the applicator tip. The placement template defines fixing point receptacles for fixing the light applicators with a defined fixing point wherein the receptacles are arranged in accordance with a three-dimensional fixing point grid structure, that corresponds to a virtual organ-specific target point grid structure for the light-emitting applicator tips in the organ that is arranged parallel-displaced relative to the target point grid structure by the distance d along the piercing axis.

Abstract: A system, for transcutaneous photodynamic therapy in an organ or organ segment of an organic body, includes a plurality of light applicators (9), a supply unit (23) and a placement template (39) placeable relative to the organic body for defined orientation of the light applicators. The light applicators include a needle-shaped insertion portion (15) for transcutaneous piercing along a piercing axis (E), a light-emitting applicator tip (19) at the distal end (13) of the insertion portion, and a fixing point (43) at a proximal distance d from the applicator tip. The placement template defines a plurality of fixing point receptacles (51) for fixing the light applicators with a defined fixing point and includes a first and second template parts (71, 75) defining first and second subsets (73, 77) of fixing point receptacles. The first template part is guidingly displaceable relative to the second template part along the piercing axis.

Abstract: A light applicator (1) executes a transcutaneous photodynamic therapy (PDT), in tissue (25) of an organic body (23) and includes a needle section (5), extending longitudinally along an insertion axis (L), and at least one light-emitting element (7) at the distal end (3) of the needle section (5). An at least partially light-transparent applicator tip (9) extends at least distally from the at least one light-emitting element (7), for insertion of the needle section (5) into the tissue (25) of the organic body (23) along the insertion axis (L). A handgrip element (19) is arranged proximally with respect to the needle section (5) for manual positioning of the light applicator (1). The handgrip element (19) can be coupled to the needle section (5) for positioning and/or insertion, and is configured to be detachable from the needle section (5) for the execution of the PDT.

Abstract: The invention relates to compounds which are suitable for treating bacterial diseases and to pharmaceutical compositions containing such compounds. The invention further relates to a kit of parts comprising such compounds and to the use of such compounds as disinfectants.

Abstract: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.

Abstract: The present invention relates to beta-O/S/N fatty acids and derivatives thereof, in particular the compounds of formula (I) as described and defined herein, and their pharmaceutical use, including their use in the treatment or prevention of bacterial as well as protozoan infections, in particular the treatment or prevention of infections with Gram-positive and/or Gram-negative bacteria and infectious diseases caused by and/or related to Gram-positive and/or Gram-negative bacteria. The invention further relates to the use of these compounds for preventing or eliminating biofilms.

Abstract: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.

Abstract: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.

Abstract: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.

Abstract: The invention at hand describes a method for the cyclization of peptides and proteins in which linear thioesters serve as substrates. The cyclization is catalyzed by thioesterase domains of NRPS or PKS cyclases. The substrates according to the present invention are composed of one linear peptide on which a charge-stabilized aromatic, heteroaromatic or araliphatic leaving group is bound. These substrates lead to higher yields and reaction rates than linear peptides able to be cyclized with methods known so far and, furthermore, allow the cyclization of such peptides which were previously not able to be cyclized.

Abstract: The present invention relates to specific beta-lactone compounds and compositions thereof for the treatment of infections, such as, e.g., infections with bacteria or infections with protozoa, in particular infections with Gram-positive and/or Gram-negative bacteria and of infectious diseases caused by or related to Gram-positive and/or Gram-negative bacteria, and to the modulation of virulence of Gram-positive and/or Gram-negative bacteria or of protozoa by specific beta-lactone compounds. The invention further relates to the use of the compounds or compositions for preventing or eliminating biofilms.

Abstract: The invention at hand describes a method for the cyclization of peptides and proteins in which linear thioesters serve as substrates. The cyclization is catalyzed by thioesterase domains of NRPS or PKS cyclases. The substrates according to the present invention are composed of one linear peptide on which a charge-stabilized aromatic, heteroaromatic or araliphatic leaving group is bound. These substrates lead to higher yields and reaction rates than linear peptides able to be cyclized with methods known so far and, furthermore, allow the cyclization of such peptides which were previously not able to be cyclized.